AN2 Therapeutics Future Growth
Future criteria checks 0/6
AN2 Therapeutics is forecast to grow earnings at 11.3% per annum. EPS is expected to grow by 14.6% per annum.
Key information
11.3%
Earnings growth rate
14.6%
EPS growth rate
| Pharmaceuticals earnings growth | 23.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Nov 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Nov 21
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -34 | N/A | N/A | 3 |
| 12/31/2025 | N/A | -33 | N/A | N/A | 4 |
| 12/31/2024 | N/A | -51 | N/A | N/A | 4 |
| 9/30/2024 | N/A | -61 | -61 | -61 | N/A |
| 6/30/2024 | N/A | -65 | -61 | -61 | N/A |
| 3/31/2024 | N/A | -66 | -59 | -59 | N/A |
| 12/31/2023 | N/A | -65 | -53 | -53 | N/A |
| 9/30/2023 | N/A | -60 | -44 | -44 | N/A |
| 6/30/2023 | N/A | -54 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -49 | -38 | -38 | N/A |
| 12/31/2022 | N/A | -43 | -33 | -33 | N/A |
| 9/30/2022 | N/A | -40 | -35 | -35 | N/A |
| 6/30/2022 | N/A | -38 | -30 | -30 | N/A |
| 3/31/2022 | N/A | -35 | -26 | -26 | N/A |
| 12/31/2021 | N/A | -28 | -20 | -20 | N/A |
| 12/31/2020 | N/A | -15 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ANTX's revenue is forecast to grow faster than the US market.
High Growth Revenue: ANTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANTX's Return on Equity is forecast to be high in 3 years time